News
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback